Abstract:OBJECTIVE:To observe the effect of dizocilpine (MK801), a noncompetitive antagonist of N-methyl-D-aspartic acid (NMDA) receptor, on P-glycoprotein (P-gp) expression after limbic seizure, and to explore whether NMDA receptor play a role in the regulation of P-gp expression during limbic seizure.METHODS:120 Wistar rats were randomly divided into 2 equal sets. 50 rats in Set 1 underwent intraperitoneal injection of lithium chloride, scopolamine, and pilocarpine so as to cause status epilepticus (SE) for 90 min. Then diazepam was given to terminate the SE. The rats were killed 0, 3, 6, 14, and 72 h after the SE respectively. The hippocampus was isolated. Realtime fluorescent quantitative RT-PCR (qRT-PCR) was used to detect the expression of multidrug resistance gene 1a (mdr1a) and mdr1b. Immunohistochemistry was used to detect the P-gp. The rats were used as controls. Another 60 rats (Set 2) were randomly divided into 3 equal groups: control group, given with normal saline (NS) only, SE group, given with NS 20 min before administration of pilocarpine, and MK801 group, given with MK801 20 min before administration of pilocarpine. The 3 groups in Set 2 were further divided into 2 equal subgroups of 10 rats to be killed 6 or 24 h after SE.RESULTS:The mdr1a expression in hippocampus within 72 h after seizure was much higher at each time point: the level of mdr1a expression instantly after the seizure was terminated was [5.6 (2.9) x 10(5) mRNA copies/40 ng total RNA], significantly higher than that of the controls [2.4 (1.1) x 10(5) mRNA copies/40 ng total RNA, P < 0.05], increased to the level of [7.6 (6.3) x 10(5), P < 0.01] 3 h after, and kept at such level till 72 h after. The msr1b expression transiently increased 2.2 and 2.4 times that of the controls respectively 3 h and 6 h after the seizure was terminated [(3.3 +/- 0.4) x 10(4), and (3.6 +/- 1.0) x 10(4), both P < 0.01)]. The expression level of mdr1a 6 h after the seizure was terminated of the MK801 group was (4.3 +/- 0.8) x 10(5) and the expression level of mdr1b 6 h after the seizure was terminated of the MK801 group was (2.0 +/- 0.7) x 10(4), both significantly lower than those of the SE group (both P < 0.01). The P-gp expression level 24 h after the seizure was terminated of the MK801 group was 26.6 +/- 5.0 pieces of microvessels/400 times field, significantly lower than that of the SE group (39.0 +/- 4.1, P < 0.01).CONCLUSION:MK801 down-regulates the overexpression of P-gp after seizure, which indicates that NMDA receptor may be involved in the regulation of P-gp expression during seizure. Therefore, it is possible to prevent the overexpression of P-gp after seizure by inhibiting NMDA receptor's overactivation effectively.

EXPRESSION OF P-GLYCOPROTEIN IN EPILETOGENIC ZONE AND TISSUE SURROUNDING THE EPILETOGENIC ZONE IN REFRACTORY EPILEPTIC PATIENTS

Expressions of SH3GL2 mRNA and Protein in the Patients with Non-lesion Intractable Epilepsy

Insights into Human Epileptogenesis with Proteomic Profiling

Diagnostic and therapeutic value of P2Y12R in epilepsy

Proteomic Differences in the Hippocampus and Cortex of Epilepsy Brain Tissue

Proteomic analysis of human epileptic neocortex predicts vascular and glial changes in epileptic regions

A Multimodal Pepstatin A Peptide-Based Nanoagent for the Molecular Imaging of P-Glycoprotein in the Brains of Epilepsy Rats

Pharmacoproteomics-based reconstruction of in vivo P-glycoprotein function at blood-brain barrier and brain distribution of substrate verapamil in pentylenetetrazole-kindled epilepsy, spontaneous epilepsy, and phenytoin treatment models

Characterization of the Expression of the ATP-Gated P2X7 Receptor Following Status Epilepticus and during Epilepsy Using a P2X7-EGFP Reporter Mouse

Seizure-Induced Up-Regulation of P-Glycoprotein at the Blood-Brain Barrier through Glutamate and Cyclooxygenase-2 Signaling

Expression and Clinical Significance of Multidrug Resistance Proteins in Brain Tumors

Expression of P-glycoprotein/caveolin-1 in blood-brain barrier

Involvement of p38 MAPK in the Drug Resistance of Refractory Epilepsy Through the Regulation Multidrug Resistance-Associated Protein 1

Increased expression of the P2X7 receptor in temporal lobe epilepsy: Animal models and clinical evidence

Altered Expression of Neuropeptide Y Receptors Caused by Focal Cortical Dysplasia in Human Intractable Epilepsy

Integrative analysis of expression profile indicates the ECM receptor and LTP dysfunction in the glioma-related epilepsy

Imaging epileptic foci in mouse models via a low-density lipoprotein receptor-related protein-1 targeting strategy

[Effect of Dizocilpine on P-glycoprotein Expression in Hippocampus in Limbic Seizure: Experiment with Rats].

Targeting microglial GLP1R in epilepsy: A novel approach to modulate neuroinflammation and neuronal apoptosis

Aerobic glycolysis imaging of epileptic foci during the inter-ictal period

A Study on Localization of Epileptogenic Zones in Refractory Epilepsy Patients with Non-Lesional MRI and CT Findings